journal article·2024-04

Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis

Ling‐Feng Zhang, Wen‐Qi Deng, Qing‐Wen Huang, Jiao‐Jiao Zhang, Yi Wang, Tian‐Jiao Zhou, Lei Xing, Hu‐Lin Jiang

Advanced Materials· Volume 36· Issue 16
Publisher page

Abstract

Abstract During liver fibrogenesis, the reciprocal crosstalk among capillarized liver sinusoidal endothelial cells (LSECs), activated hepatic stellate cells (HSCs), and dysfunctional hepatocytes constructs a self‐amplifying vicious cycle, greatly exacerbating the disease condition and weakening therapeutic effect. Limited by the malignant cellular interactions, the previous single‐cell centric treatment approaches show unsatisfactory efficacy and fail to meet clinical demand. Herein, a vicious cycle‐breaking strategy is proposed to target and repair pathological cells separately to terminate the malignant progression of liver fibrosis. Chondroitin sulfate‐modified and vismodegib‐loaded nanoparticles (CS‐NPs/VDG) are designed to efficiently normalize the fenestrae phenotype of LSECs and restore HSCs to quiescent state by inhibiting Hedgehog signaling pathway. In addition, glycyrrhetinic acid‐modified and silybin‐loaded nanoparticles (GA‐NPs/SIB) are prepared to restore hepatocytes function by relieving oxidative stress. The results show successful interruption of vicious cycle as well as distinct fibrosis resolution in two animal models through multiregulation of the pathological cells. This work not only highlights the significance of modulating cellular crosstalk but also provides a promising avenue for developing antifibrotic regimens.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver physiology and pathology · Liver Disease Diagnosis and Treatment · Hepatocellular Carcinoma Treatment and Prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 China

College of Pharmacy Yanbian University Yanji 133002 China

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals China Pharmaceutical University Nanjing 210009 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (45)

Show source-provided references
1. 10.1002/hep.3228510.1002/hep.32285 ↗
2. 10.1016/j.jhep.2023.03.01710.1016/j.jhep.2023.03.017 ↗
3. 10.1146/annurev-pathol-011110-13024610.1146/annurev-pathol-011110-130246 ↗
4. 10.1038/s41575-020-00408-y10.1038/s41575-020-00408-y ↗
5. 10.1038/s41591-018-0104-910.1038/s41591-018-0104-9 ↗
6. 10.1126/scitranslmed.add394910.1126/scitranslmed.add3949 ↗
7. 10.1038/s41467-022-29186-810.1038/s41467-022-29186-8 ↗
8. 10.1016/j.jconrel.2020.02.04910.1016/j.jconrel.2020.02.049 ↗
9. 10.1016/j.biomaterials.2019.11961610.1016/j.biomaterials.2019.119616 ↗
10. 10.1016/j.phrs.2020.10472010.1016/j.phrs.2020.104720 ↗
11. 10.1016/j.molcel.2019.07.02810.1016/j.molcel.2019.07.028 ↗
12. 10.1126/science.abq520210.1126/science.abq5202 ↗
13. 10.1016/j.cmet.2021.06.00510.1016/j.cmet.2021.06.005 ↗
14. 10.1172/JCI16695410.1172/JCI166954 ↗
15. 10.1016/j.jhep.2015.02.03910.1016/j.jhep.2015.02.039 ↗
16. 10.1016/j.jhep.2016.04.01810.1016/j.jhep.2016.04.018 ↗
17. 10.1016/j.jhep.2017.10.01710.1016/j.jhep.2017.10.017 ↗
18. 10.1136/gutjnl-2011-30149410.1136/gutjnl-2011-301494 ↗
19. 10.3389/fimmu.2022.93619610.3389/fimmu.2022.936196 ↗
20. 10.1002/hep.2737610.1002/hep.27376 ↗
21. 10.1007/s00292-020-00802-y10.1007/s00292-020-00802-y ↗
22. 10.1016/j.jhep.2016.07.00910.1016/j.jhep.2016.07.009 ↗
23. 10.1021/acsnano.2c0385810.1021/acsnano.2c03858 ↗
24. 10.1038/s41575-020-00411-310.1038/s41575-020-00411-3 ↗
25. 10.1136/gutjnl-2017-31569110.1136/gutjnl-2017-315691 ↗
26. 10.1002/hep.2400110.1002/hep.24001 ↗
27. 10.1126/scitranslmed.adc965310.1126/scitranslmed.adc9653 ↗
28. 10.1146/annurev-nutr-062220-10520010.1146/annurev-nutr-062220-105200 ↗
29. 10.1016/j.jhep.2023.03.03910.1016/j.jhep.2023.03.039 ↗
30. 10.1016/j.phrs.2020.10472010.1016/j.phrs.2020.104720 ↗
31. 10.7150/thno.7725610.7150/thno.77256 ↗
32. 10.1097/HEP.000000000000038710.1097/HEP.0000000000000387 ↗
33. 10.1152/ajpgi.00358.201810.1152/ajpgi.00358.2018 ↗
34. 10.1080/1061186X.2017.136700610.1080/1061186X.2017.1367006 ↗
35. 10.1053/j.gastro.2011.12.01710.1053/j.gastro.2011.12.017 ↗
36. 10.1016/j.carbpol.2021.11796410.1016/j.carbpol.2021.117964 ↗
37. 10.1002/adma.20210645610.1002/adma.202106456 ↗
38. 10.3109/0898210090334792310.3109/08982100903347923 ↗
39. 10.1016/j.jddst.2020.10217410.1016/j.jddst.2020.102174 ↗
40. 10.1126/scitranslmed.ade315710.1126/scitranslmed.ade3157 ↗
41. 10.1097/HEP.000000000000020710.1097/HEP.0000000000000207 ↗
42. 10.1016/j.cell.2023.07.01710.1016/j.cell.2023.07.017 ↗
43. 10.1002/hep.3266210.1002/hep.32662 ↗
44. 10.15557/JoU.2020.002810.15557/JoU.2020.0028 ↗
45. 10.1038/s42255-022-00700-y10.1038/s42255-022-00700-y ↗